The Diamond Action Plan is targeted primarily to biologics, which fall under the category of emerging biotechnology. Biologics of note in Taiwan include a vaccine produced by Adimmune Corporation, and the monoclonal antibody AIDS drug TMD-355 of TaiMed Biotech, which is now in the midst of phase II clinical testing.
此次「生技起飛」方案所加碼推動的，主要是新興生技產業版圖中的「生物製劑」部分，諸如國光生技生產的疫苗，以及中裕新藥（前身是宇昌生技）已經進入第二期臨床試驗的單株抗體抗愛滋新藥「TMD-355」。